Table 1 Patients characteristics. Comparison between the oncoplastic surgery cohort (ONC) and the non-oncoplastic sugery cohort (NONC)
From: Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients
Variable | N | ONC | N | NONC | p value |
|---|---|---|---|---|---|
N. group | 288 | 677 | |||
Age | |||||
Mean ± SD | 288 (100%) | 55.8 ± 10.5 | 677 (100%) | 58.2 ± 10.4 | 0.001 |
Grading | |||||
G1 | 273 (94.8%) | 21 (7.7%) | 634 (93.6%) | 87 (13.7%) | < 0.001 |
G2 | 129 (47.1%) | 340 (53.5%) | |||
G3/4 | 124 (45.0%) | 209 (32.9%) | |||
T stage | |||||
yT0 | 288 (100%) | 4 (1.4%) | 677 (100%) | 21 (3.1%) | 0.012* |
CIS | 12 (4.2%) | 36 (5.3%) | |||
Tmic | 2 (0.7%) | 2 (0.3%) | |||
T1a | 3 (1.0%) | 44 (6.5%) | |||
T1b | 48 (16.7%) | 110 (16.2%) | |||
T1c | 135 (46.9%) | 316 (46.7%) | |||
T2 | 77 (26.7%) | 145 (21.4%) | |||
T3 | 4 (1.4%) | 1 (0.1%) | |||
T4 | 3 (1.0%) | 2 (0.3%) | |||
N stage | |||||
N0 | 288 (100%) | 192 (66.7%) | 677 (100%) | 512 (75.6%) | 0.013 |
N1 | 62 (21.5%) | 120 (17.7%) | |||
N2 | 23 (8.0%) | 33 (4.9%) | |||
N3 | 11 (3.8%) | 12 (1.8%) | |||
Margins | |||||
Negative | 288 (100%) | 283 (98.3%) | 677 (100%) | 668 (98.7%) | 0.307 |
Positive | 5 (0.7%) | 9 (1.3%) | |||
Estrogen receptor status | |||||
Negative | 286 (99.3%) | 58 (20.3%) | 661 (97.6%) | 180 (27.2%) | 0.024 |
Positive | 228 (79.7%) | 481 (72.8%) | |||
Progesteron receptor status | |||||
Negative | 285 (99.0%) | 108 (38.9%) | 661 (97.6%) | 243 (36.8%) | 0.741 |
Positive | 177 (62.1%) | 481 (63.2%) | |||
Her2neu | |||||
Negative | 288 (100%) | 246 (85.4%) | 677 (100%) | 605 (89.4%) | 0.071 |
Positive | 42 (14.6%) | 71 (10.6%) | |||
Site | |||||
Right breast | 288 (100%) | 154 (53.5%) | 677 (100%) | 313 (46.2%) | 0.039 |
Left breast | 134 (46.5%) | 364 (53.8%) | |||
Neoadjuvant Chemotherapy | |||||
No | 288 (100%) | 267 (92.7%) | 677 (100%) | 605 (89.4%) | 0.107 |
Yes | 21 (7.3%) | 72 (10.6%) | |||
Adjuvant Chemotherapy | |||||
No | 288 (100%) | 124 (43.1%) | 677 (100%) | 384 (56.7%) | < 0.001 |
Yes | 164 (56.9%) | 293 (43.3%) | |||
Hormone therapy | |||||
No | 288 (100%) | 53 (18.4%) | 677 (100%) | 171 (25.3%) | 0.021 |
Yes | 235 (81.6%) | 506 (74.7%) | |||
Trastuzumab | |||||
No | 283 (98.3%) | 275 (97.2%) | 675 (99.7%) | 660 (81.5%) | 0.577 |
Yes | 8 (2.8%) | 15 (2.2%) | |||